Loading…
Genmab A/S is projected to rise to $33.42 by 2027, a +15% move from its current price of $29.00. GMAB is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $28.44 | $29.00 | $29.57 | 0.00% |
| Jul 13 | $28.22 | $29.00 | $29.81 | 0.00% |
| Jul 14 | $28.04 | $29.00 | $29.99 | 0.00% |
| Jul 15 | $27.90 | $29.00 | $30.15 | +0.01% |
| Jul 16 | $27.77 | $29.00 | $30.29 | +0.01% |
| Jul 17 | $27.66 | $29.00 | $30.41 | +0.01% |
| Jul 18 | $27.55 | $29.00 | $30.53 | +0.01% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $27.55 | $29.00 | $30.53 | +0.01% |
| Week 2 | $26.98 | $29.01 | $31.19 | +0.02% |
| Week 3 | $26.54 | $29.01 | $31.70 | +0.03% |
| Week 4 | $26.18 | $29.01 | $32.14 | +0.04% |
| Week 5 | $25.87 | $29.01 | $32.54 | +0.04% |
| Week 6 | $25.59 | $29.02 | $32.90 | +0.05% |
| Week 7 | $25.34 | $29.02 | $33.24 | +0.06% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Genmab A/S is a biotechnology company that develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark.
The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.
It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and NSCLC; Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. It has collaboration agreements with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx.
Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
GMAB is currently priced at $29.54 with a market capitalization of $18.14B and a rank of 624. This places the stock among mid-cap to large-cap biotech listings with a broad clinical pipeline and partnerships. The latest technical backdrop is bullish, and the stock sits near notable levels that could influence near-term moves.
The 30-day technical picture shows a bullish stance with RSI(14) at 70 and moving averages at $26.31 (SMA50) and $29.23 (SMA200). The price faces support at $23.85 and resistance at $29.54, with a 30-day trading range of $25.94 to $33.64. Annualized volatility sits at 40%, signaling elevated variability around the price path.
Forecasts imply a rising trajectory over the longer horizon. The average price in 2026 is $29.54 with a max of $37.92; the path then climbs to $34.52 (avg) in 2027, $42.87 in 2028, $49.21 in 2029, and $54.41 in 2030. The outlook extends to later years with stronger upside, including $122.33 in 2040 and $267.26 in 2050 on average, alongside substantial max values along the way.
A major floor 25.5% below — a decisive break under it would weaken the trend.
The nearest floor, 17.8% below — buyers have tended to step in here.
Price is pressing into resistance (2.7% away) — a breakout level to watch.
A major ceiling 15.4% above — clearing it would confirm fresh momentum.
Key GMAB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of GMAB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $29.10 | Sell | $29.00 | Buy |
| MA 10 | $28.13 | Buy | $28.29 | Buy |
| MA 20 | $26.76 | Buy | $27.38 | Buy |
| MA 50 | $26.42 | Buy | $26.88 | Buy |
| MA 100 | $27.00 | Buy | $27.32 | Buy |
| MA 200 | $29.24 | Sell | $27.47 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 64.71 | Neutral |
| Stoch RSI (14) | 64.40 | Neutral |
| CCI (20) | 99.16 | Neutral |
| Williams %R (14) | -18.71 | Info |
| MACD (12,26,9) | 0.39 | Buy |
| ROC (12) | 11.80 | Buy |
| Bollinger %B (20,2) | 0.84 | Neutral |
| Stochastic %K (14) | 81.29 | Sell |
| TRIX (15) | 0.28 | Buy |
| Awesome (5,34) | 2.82 | Buy |
| Ultimate (7,14,28) | 69.98 | Neutral |
| Momentum (10) | 2.86 | Buy |
| Aroon Osc (25) | 96.00 | Buy |
| Hull MA (9) | 29.94 | Sell |
| ADX (14) | 22.02 | Buy |
| ATR (14) | 0.50 | Info |
In the next 30 days, the sentiment is labeled BULLISH and the RSI(14) is 70, indicating strong near-term momentum.
Key levels to watch include a support at $23.85 and a resistance at $29.54, with the SMA50 at $26.31 and the SMA200 at $29.23. The 30-day price range spans from $25.94 to $33.64, outlining the near-term trading band.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $23.85 | $29.00 | $37.04 | 0% | Neutral | |
| $27.32 | $33.42 | $42.77 | +15% | Neutral | |
| $33.13 | $41.32 | $54.35 | +42% | Bullish | |
| $37.29 | $47.24 | $63.50 | +63% | Bullish | |
| $40.45 | $51.96 | $71.13 | +79% | Bullish | |
| $45.60 | $59.31 | $82.51 | +105% | Bullish | |
| $45.48 | $59.85 | $84.47 | +106% | Bullish | |
| $47.48 | $63.16 | $90.33 | +118% | Bullish | |
| $53.20 | $71.49 | $103.49 | +147% | Bullish | |
| $58.85 | $79.86 | $116.92 | +175% | Bullish | |
| $80.43 | $114.00 | $175.10 | +293% | Bullish | |
| $161.74 | $246.50 | $406.43 | +750% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $23.85 | $29.00 | $34.86 | +0.00% |
| August 2026 | $24.92 | $29.18 | $34.94 | +0.64% |
| September 2026 | $24.67 | $29.03 | $35.04 | -0.52% |
| October 2026 | $25.28 | $29.88 | $36.30 | +2.90% |
| November 2026 | $25.58 | $30.34 | $37.07 | +1.56% |
| December 2026 | $25.34 | $30.16 | $37.04 | -0.59% |
Click any year to see its month-by-month GMAB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The GMAB price prediction for 2026 points to an average of $29.00 (low $23.85, high $37.04) — a potential gain of 0% on today's $29.00. Price action looks broadly range-bound.
In 2027, GMAB is projected to trade between $27.32 and $42.77, averaging $33.42 — a potential gain of +15% from today's $29.00. That is up +15% on the projected 2026 average. A consolidation phase looks the most probable path here.
Genmab A/S's 2028 outlook centres on $41.32, within a $33.13 to $54.35 range. That is up +24% on the projected 2027 average. That marks a +42% change versus current levels. Momentum favours further upside here.
By 2029, GMAB could reach as high as $63.50, with a base case around $47.24 and support toward $37.29 — roughly +63% from $29.00. Buyers look set to stay in control over this stretch.
Expect GMAB to range from $40.45 to $71.13 through 2030. The $51.96 average target implies a +79% move from current prices. That is up +10% on the projected 2029 average. Momentum favours further upside here.
The GMAB price prediction for 2031 points to an average of $59.31 (low $45.60, high $82.51) — a potential gain of +105% on today's $29.00. Buyers look set to stay in control over this stretch.
In 2032, GMAB is projected to trade between $45.48 and $84.47, averaging $59.85 — a potential gain of +106% from today's $29.00. That is up +1% on the projected 2031 average. Momentum favours further upside here.
Genmab A/S's 2033 outlook centres on $63.16, within a $47.48 to $90.33 range. That is up +6% on the projected 2032 average. That marks a +118% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, GMAB could reach as high as $103.49, with a base case around $71.49 and support toward $53.20 — roughly +147% from $29.00. Momentum favours further upside here.
Expect GMAB to range from $58.85 to $116.92 through 2035. The $79.86 average target implies a +175% move from current prices. That is up +12% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The GMAB price prediction for 2040 points to an average of $114.00 (low $80.43, high $175.10) — a potential gain of +293% on today's $29.00. Momentum favours further upside here.
In 2050, GMAB is projected to trade between $161.74 and $406.43, averaging $246.50 — a potential gain of +750% from today's $29.00. That is up +116% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in GMAB today (≈ 34.482759 GMAB) could be worth
$8,500.05
+$7,500.05 (+750%) by 2050 · US Dollar
Based on the average projected GMAB price of $246.5 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in GMABwould be worth at today's price.
$1,000 invested in GMAB on Jul 10, 2025 (≈ 45.745653 GMAB) would be worth
$1,326.62
+$326.62 (+32.7%) today · 1.33× · US Dollar
Based on a GMAB entry price of $21.86 vs. today's $29.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $28.51 | $1,017.01 | +1.7% |
| 1 month ago | $24.49 | $1,184.16 | +18.4% |
| 3 months ago | $28.25 | $1,026.55 | +2.7% |
| 6 months ago | $33.95 | $854.2 | -14.6% |
| 1 year ago | $21.86 | $1,326.62 | +32.7% |
| All time (5.0y) ago | $43.83 | $661.65 | -33.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our GMAB forecast.
Our base-case forecast reaches $58.00 around 2031.
Implied market cap at $58.00: $35.61B
The multi-year forecast envisions continued upside, with the 2027 average at $34.52 and the 2028 average at $42.87, followed by 2029 at $49.21 and 2030 at $54.41. By 2030 the forecast implies an 84.2% return (ROI) on the base level, and by 2040 the average price is projected at $122.33 with a 314.1% ROI. By 2050 the average rises to $267.26 and the ROI reaches 804.7%, signaling substantial long-run appreciation if the trajectory holds.
The longer-horizon outlook includes yearly steps through 2031–2035 and beyond, with 2031 at $62.20, 2032 at $62.97, 2033 at $66.82, 2034 at $75.94, and 2035 at $85.20 on average, culminating in higher targets in 2040 and 2050 as noted. The max forecasts accompany higher potential prices, for instance 2034 at $110.30 and 2050 at $442.79. These projections indicate meaningful upside but carry the inherent uncertainty of future markets; they are estimates, not guarantees.
Tap a question to reveal the answer.
The forecast shows an average price of $54.41 in 2030, with a min of $42.28 and a max of $74.68; the implied ROI is 84.2% and sentiment is BULLISH.
The long-term picture points to upside, with averages rising to $62.20 in 2031 and $267.26 by 2050, and ROI values up to 804.7% in 2050. The 2026 figure is neutral with an average of $29.54 and ROI of 0%, indicating uncertainty and that outcomes are not guaranteed.
Yes, the forecast max reaches $188.64 by 2040 and $442.79 by 2050, meaning $100 could occur along the projected path within the stated horizons.
The 30-day range is $25.94 to $33.64.
Current price is $29.54 and market cap is $18.14B.
Genmab A/S Community Discussion
0Share your Genmab A/S price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.